International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management

Elsa Dent, J. E. Morley, A. J. Cruz-Jentoft, H. Arai, S. B. Kritchevsky, J. Guralnik, J. M. Bauer, M. Pahor, B. C. Clark, M. Cesari, J. Ruiz, C. C. Sieber, M. Aubertin-Leheudre, D. L. Waters, R. Visvanathan, F. Landi, D. T. Villareal, R. Fielding, C. W. Won, O. TheouF. C. Martin, B. Dong, J. Woo, L. Flicker, L. Ferrucci, R. A. Merchant, L. Cao, T. Cederholm, S. M.L. Ribeiro, L. Rodríguez-Mañas, S. D. Anker, J. Lundy, L. M. Gutiérrez Robledo, I. Bautmans, I. Aprahamian, J. M.G.A. Schols, M. Izquierdo, B. Vellas

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objectives: Sarcopenia, defined as an age-associated loss of skeletal muscle function and muscle mass, occurs in approximately 6 - 22 % of older adults. This paper presents evidence-based clinical practice guidelines for screening, diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research (ICSFR). Methods: To develop the guidelines, we drew upon the best available evidence from two systematic reviews paired with consensus statements by international working groups on sarcopenia. Eight topics were selected for the recommendations: (i) defining sarcopenia; (ii) screening and diagnosis; (iii) physical activity prescription; (iv) protein supplementation; (v) vitamin D supplementation; (vi) anabolic hormone prescription; (vii) medications under development; and (viii) research. The ICSFR task force evaluated the evidence behind each topic including the quality of evidence, the benefitharm balance of treatment, patient preferences/values, and cost-effectiveness. Recommendations were graded as either strong or conditional (weak) as per the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Consensus was achieved via one face-to-face workshop and a modified Delphi process. Recommendations: We make a conditional recommendation for the use of an internationally accepted measurement tool for the diagnosis of sarcopenia including the EWGSOP and FNIH definitions, and advocate for rapid screening using gait speed or the SARC-F. To treat sarcopenia, we strongly recommend the prescription of resistance-based physical activity, and conditionally recommend protein supplementation/a protein-rich diet. No recommendation is given for Vitamin D supplementation or for anabolic hormone prescription. There is a lack of robust evidence to assess the strength of other treatment options.

Original languageEnglish
Pages (from-to)1148-1161
JournalJournal of Nutrition, Health and Aging
Volume22
Issue number10
DOIs
Publication statusPublished - 2018

Fingerprint

Sarcopenia
Practice Guidelines
Prescriptions
Advisory Committees
Vitamin D
Research
Hormones
Proteins
Patient Preference
Evidence-Based Practice
Practice Management
Cost-Benefit Analysis
Skeletal Muscle
Guidelines
Diet
Education
Muscles

Keywords

  • 80 and over
  • aged
  • muscle strength
  • practice guideline
  • Sarcopenia/diagnosis
  • sarcopenia/therapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Geriatrics and Gerontology

Cite this

Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., ... Vellas, B. (2018). International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. Journal of Nutrition, Health and Aging, 22(10), 1148-1161. https://doi.org/10.1007/s12603-018-1139-9

International Clinical Practice Guidelines for Sarcopenia (ICFSR) : Screening, Diagnosis and Management. / Dent, Elsa; Morley, J. E.; Cruz-Jentoft, A. J.; Arai, H.; Kritchevsky, S. B.; Guralnik, J.; Bauer, J. M.; Pahor, M.; Clark, B. C.; Cesari, M.; Ruiz, J.; Sieber, C. C.; Aubertin-Leheudre, M.; Waters, D. L.; Visvanathan, R.; Landi, F.; Villareal, D. T.; Fielding, R.; Won, C. W.; Theou, O.; Martin, F. C.; Dong, B.; Woo, J.; Flicker, L.; Ferrucci, L.; Merchant, R. A.; Cao, L.; Cederholm, T.; Ribeiro, S. M.L.; Rodríguez-Mañas, L.; Anker, S. D.; Lundy, J.; Gutiérrez Robledo, L. M.; Bautmans, I.; Aprahamian, I.; Schols, J. M.G.A.; Izquierdo, M.; Vellas, B.

In: Journal of Nutrition, Health and Aging, Vol. 22, No. 10, 2018, p. 1148-1161.

Research output: Contribution to journalArticle

Dent, E, Morley, JE, Cruz-Jentoft, AJ, Arai, H, Kritchevsky, SB, Guralnik, J, Bauer, JM, Pahor, M, Clark, BC, Cesari, M, Ruiz, J, Sieber, CC, Aubertin-Leheudre, M, Waters, DL, Visvanathan, R, Landi, F, Villareal, DT, Fielding, R, Won, CW, Theou, O, Martin, FC, Dong, B, Woo, J, Flicker, L, Ferrucci, L, Merchant, RA, Cao, L, Cederholm, T, Ribeiro, SML, Rodríguez-Mañas, L, Anker, SD, Lundy, J, Gutiérrez Robledo, LM, Bautmans, I, Aprahamian, I, Schols, JMGA, Izquierdo, M & Vellas, B 2018, 'International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management', Journal of Nutrition, Health and Aging, vol. 22, no. 10, pp. 1148-1161. https://doi.org/10.1007/s12603-018-1139-9
Dent, Elsa ; Morley, J. E. ; Cruz-Jentoft, A. J. ; Arai, H. ; Kritchevsky, S. B. ; Guralnik, J. ; Bauer, J. M. ; Pahor, M. ; Clark, B. C. ; Cesari, M. ; Ruiz, J. ; Sieber, C. C. ; Aubertin-Leheudre, M. ; Waters, D. L. ; Visvanathan, R. ; Landi, F. ; Villareal, D. T. ; Fielding, R. ; Won, C. W. ; Theou, O. ; Martin, F. C. ; Dong, B. ; Woo, J. ; Flicker, L. ; Ferrucci, L. ; Merchant, R. A. ; Cao, L. ; Cederholm, T. ; Ribeiro, S. M.L. ; Rodríguez-Mañas, L. ; Anker, S. D. ; Lundy, J. ; Gutiérrez Robledo, L. M. ; Bautmans, I. ; Aprahamian, I. ; Schols, J. M.G.A. ; Izquierdo, M. ; Vellas, B. / International Clinical Practice Guidelines for Sarcopenia (ICFSR) : Screening, Diagnosis and Management. In: Journal of Nutrition, Health and Aging. 2018 ; Vol. 22, No. 10. pp. 1148-1161.
@article{364b32704cd24ec2b5172e556c0c3fb8,
title = "International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management",
abstract = "Objectives: Sarcopenia, defined as an age-associated loss of skeletal muscle function and muscle mass, occurs in approximately 6 - 22 {\%} of older adults. This paper presents evidence-based clinical practice guidelines for screening, diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research (ICSFR). Methods: To develop the guidelines, we drew upon the best available evidence from two systematic reviews paired with consensus statements by international working groups on sarcopenia. Eight topics were selected for the recommendations: (i) defining sarcopenia; (ii) screening and diagnosis; (iii) physical activity prescription; (iv) protein supplementation; (v) vitamin D supplementation; (vi) anabolic hormone prescription; (vii) medications under development; and (viii) research. The ICSFR task force evaluated the evidence behind each topic including the quality of evidence, the benefitharm balance of treatment, patient preferences/values, and cost-effectiveness. Recommendations were graded as either strong or conditional (weak) as per the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Consensus was achieved via one face-to-face workshop and a modified Delphi process. Recommendations: We make a conditional recommendation for the use of an internationally accepted measurement tool for the diagnosis of sarcopenia including the EWGSOP and FNIH definitions, and advocate for rapid screening using gait speed or the SARC-F. To treat sarcopenia, we strongly recommend the prescription of resistance-based physical activity, and conditionally recommend protein supplementation/a protein-rich diet. No recommendation is given for Vitamin D supplementation or for anabolic hormone prescription. There is a lack of robust evidence to assess the strength of other treatment options.",
keywords = "80 and over, aged, muscle strength, practice guideline, Sarcopenia/diagnosis, sarcopenia/therapy",
author = "Elsa Dent and Morley, {J. E.} and Cruz-Jentoft, {A. J.} and H. Arai and Kritchevsky, {S. B.} and J. Guralnik and Bauer, {J. M.} and M. Pahor and Clark, {B. C.} and M. Cesari and J. Ruiz and Sieber, {C. C.} and M. Aubertin-Leheudre and Waters, {D. L.} and R. Visvanathan and F. Landi and Villareal, {D. T.} and R. Fielding and Won, {C. W.} and O. Theou and Martin, {F. C.} and B. Dong and J. Woo and L. Flicker and L. Ferrucci and Merchant, {R. A.} and L. Cao and T. Cederholm and Ribeiro, {S. M.L.} and L. Rodr{\'i}guez-Ma{\~n}as and Anker, {S. D.} and J. Lundy and {Guti{\'e}rrez Robledo}, {L. M.} and I. Bautmans and I. Aprahamian and Schols, {J. M.G.A.} and M. Izquierdo and B. Vellas",
year = "2018",
doi = "10.1007/s12603-018-1139-9",
language = "English",
volume = "22",
pages = "1148--1161",
journal = "Journal of Nutrition, Health and Aging",
issn = "1279-7707",
publisher = "Springer Paris",
number = "10",

}

TY - JOUR

T1 - International Clinical Practice Guidelines for Sarcopenia (ICFSR)

T2 - Screening, Diagnosis and Management

AU - Dent, Elsa

AU - Morley, J. E.

AU - Cruz-Jentoft, A. J.

AU - Arai, H.

AU - Kritchevsky, S. B.

AU - Guralnik, J.

AU - Bauer, J. M.

AU - Pahor, M.

AU - Clark, B. C.

AU - Cesari, M.

AU - Ruiz, J.

AU - Sieber, C. C.

AU - Aubertin-Leheudre, M.

AU - Waters, D. L.

AU - Visvanathan, R.

AU - Landi, F.

AU - Villareal, D. T.

AU - Fielding, R.

AU - Won, C. W.

AU - Theou, O.

AU - Martin, F. C.

AU - Dong, B.

AU - Woo, J.

AU - Flicker, L.

AU - Ferrucci, L.

AU - Merchant, R. A.

AU - Cao, L.

AU - Cederholm, T.

AU - Ribeiro, S. M.L.

AU - Rodríguez-Mañas, L.

AU - Anker, S. D.

AU - Lundy, J.

AU - Gutiérrez Robledo, L. M.

AU - Bautmans, I.

AU - Aprahamian, I.

AU - Schols, J. M.G.A.

AU - Izquierdo, M.

AU - Vellas, B.

PY - 2018

Y1 - 2018

N2 - Objectives: Sarcopenia, defined as an age-associated loss of skeletal muscle function and muscle mass, occurs in approximately 6 - 22 % of older adults. This paper presents evidence-based clinical practice guidelines for screening, diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research (ICSFR). Methods: To develop the guidelines, we drew upon the best available evidence from two systematic reviews paired with consensus statements by international working groups on sarcopenia. Eight topics were selected for the recommendations: (i) defining sarcopenia; (ii) screening and diagnosis; (iii) physical activity prescription; (iv) protein supplementation; (v) vitamin D supplementation; (vi) anabolic hormone prescription; (vii) medications under development; and (viii) research. The ICSFR task force evaluated the evidence behind each topic including the quality of evidence, the benefitharm balance of treatment, patient preferences/values, and cost-effectiveness. Recommendations were graded as either strong or conditional (weak) as per the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Consensus was achieved via one face-to-face workshop and a modified Delphi process. Recommendations: We make a conditional recommendation for the use of an internationally accepted measurement tool for the diagnosis of sarcopenia including the EWGSOP and FNIH definitions, and advocate for rapid screening using gait speed or the SARC-F. To treat sarcopenia, we strongly recommend the prescription of resistance-based physical activity, and conditionally recommend protein supplementation/a protein-rich diet. No recommendation is given for Vitamin D supplementation or for anabolic hormone prescription. There is a lack of robust evidence to assess the strength of other treatment options.

AB - Objectives: Sarcopenia, defined as an age-associated loss of skeletal muscle function and muscle mass, occurs in approximately 6 - 22 % of older adults. This paper presents evidence-based clinical practice guidelines for screening, diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research (ICSFR). Methods: To develop the guidelines, we drew upon the best available evidence from two systematic reviews paired with consensus statements by international working groups on sarcopenia. Eight topics were selected for the recommendations: (i) defining sarcopenia; (ii) screening and diagnosis; (iii) physical activity prescription; (iv) protein supplementation; (v) vitamin D supplementation; (vi) anabolic hormone prescription; (vii) medications under development; and (viii) research. The ICSFR task force evaluated the evidence behind each topic including the quality of evidence, the benefitharm balance of treatment, patient preferences/values, and cost-effectiveness. Recommendations were graded as either strong or conditional (weak) as per the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Consensus was achieved via one face-to-face workshop and a modified Delphi process. Recommendations: We make a conditional recommendation for the use of an internationally accepted measurement tool for the diagnosis of sarcopenia including the EWGSOP and FNIH definitions, and advocate for rapid screening using gait speed or the SARC-F. To treat sarcopenia, we strongly recommend the prescription of resistance-based physical activity, and conditionally recommend protein supplementation/a protein-rich diet. No recommendation is given for Vitamin D supplementation or for anabolic hormone prescription. There is a lack of robust evidence to assess the strength of other treatment options.

KW - 80 and over

KW - aged

KW - muscle strength

KW - practice guideline

KW - Sarcopenia/diagnosis

KW - sarcopenia/therapy

UR - http://www.scopus.com/inward/record.url?scp=85057136227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057136227&partnerID=8YFLogxK

U2 - 10.1007/s12603-018-1139-9

DO - 10.1007/s12603-018-1139-9

M3 - Article

AN - SCOPUS:85057136227

VL - 22

SP - 1148

EP - 1161

JO - Journal of Nutrition, Health and Aging

JF - Journal of Nutrition, Health and Aging

SN - 1279-7707

IS - 10

ER -